StockData
Quantum Biopharma Ltd. logo

Quantum Biopharma Ltd. (QNTM) company profile

QNTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 26, 2026Score 1/30
$1.59+0.15 (+10.42%)

Close on Nov 17, 2026Market cap $6.18MP/E –Yield –

About Quantum Biopharma

Pharmaceutical Preparations, SIC 2834

Quantum BioPharma Ltd. is a biopharmaceutical company engaged in the research and development of drug candidates for neurodegenerative diseases and alcohol misuse, as well as functional beverages. Its core clinical pipeline features Lucid-MS (Lucid-21-302), a product candidate targeted at preventing and reversing myelin degradation in the treatment of multiple sclerosis. The company also advances treatments for alcohol misuse and holds rights to related commercial technologies. Its customer base and commercial target audience include healthcare systems, physicians, patients, healthcare payors, and retail consumers who purchase its functional beverage products through commercial distribution partners.

The company operates internationally, conducting business activities, clinical studies, and strategic partnerships across Canada, the United States, and Australia. Corporate administration and executive management operate out of its principal executive offices in Toronto, Ontario, Canada.

Summary of the business section of Quantum Biopharma's latest annual report, written by StockData.

Company profile

Company

Legal name
Quantum Biopharma Ltd.
Headquarters
Toronto, Ontario, Canada
Address
1 Adelaide Street East, Suite 801 M5C 2V9
Phone
(416) 854-8884
Employees
7, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
A6
Fiscal year ends
December 31
Auditor
MNP LLP, Mississauga, Canada

Stock & identifiers

Ticker
QNTM
Former tickers
HUGE until Mar 31, 2025
Exchange
Nasdaq
IPO date
Jun 8, 2018
Shares outstanding
4M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Emerging growth company
Stock splits
1-for-65 reverse, Mar 28, 2025; 1-for-65 reverse, Aug 15, 2024; 1-for-201 reverse, Oct 16, 2019
SEC CIK
1771885
CUSIP
74764Y205
ISIN
CA74764Y2050
FIGI
BBG00L45SFK1
Share class FIGI
BBG00L1C7XW0
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

No recent ownership filings by officers or directors

Quantum Biopharma's leadership is listed in its proxy statement (Form DEF 14A).

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 7 full-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Aug 15, 2024Name changeName changed from FSD Pharma Inc. to Quantum Biopharma Ltd.

See a number that looks wrong?